- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02340559
Effectiveness of Meta-Cognitive Training (EMC) in People With Psychosis of Brief Evolution.
Effectiveness of Meta-Cognitive Training (EMC) on Symptmos, Metacognition, Social and Neuropsychological Functioning in People With Psychosis of Brief Evolution
The purpose of this study is to assess the effectiveness of Meta-Cognitive Training (EMC) in people with a brief psychotic disorder, especially positive symptoms.
The secondary objectives would be to assess the effect of EMC on metacognition (cognitive distortions and deficits in theory of mind), psychosocial functioning and quality of life, neuropsychological functioning and gender, as well as determine the changes produced by EMC in the insight of each session and the maintenance of the effects of EMC program at six months of treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a randomized clinical trial in which a group will receive the Meta-Cognitive Training (EMC) and a control group will receive a journal workshop.
The evaluator will be blind to the group that owns the patients included. The total simple will be of 122 people with a psychotic disorder, less than 5 years of evolution and a score at or above 3 on the PANSS during the last year. Patients should be attended in one of the next services: Parc Sanitari Sant Joan de Déu, Corporació Sanitària Parc Taulí, Hospital de la Santa Creu i Sant Pau, Hospital Clínic de Valencia, Centre d´Higiene Mental de les Corts, Institut d´Assitència Sanitària Girona, Servicio Andaluz de Granada, Málaga y Jaén. The assessment was performed at baseline, at the end of treatment and six month follow-up.
The assessment includes: psychopathology and insight ( PANSS, PSYRATS, PDI, GAF, BDI, BCIS, Sumd), meta-cognition (jumping to conclusions, IPSAQ, TCI), neuropsychology (WCST, TMT, CPT-II, TAVEC, WAIS) and social functioning and quality of life (EFS, DAS-SV, SLDS). The insight will be assessed at the final of each session (BCIS). The treatment and control group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group. The EMC group material is translated and validated in Spanish by investigators of the team.
The primary analysis variable is the difference between the scores of experimental and control group in the symptoms scales (especially positive). Secondary outcomes will change in other assessments of social functioning, metacognition (cognitive distortions and theory of mind) and neuropsychological variables. Were analyzed using regression and ANCOVA methods with SPSS 19.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of : schizophrenia, schizoaffective disorder, brief psychotic disorder, delusional disorder, schizophreniform disorder, psychotic disorder not otherwise specified.
- Less than 5 years of evolution.
- Score at or above 4 on the PANSS during the last year (delusions, grandiosity, suspiciousness).
Exclusion Criteria:
- Neurological disorder which impairs cognition.
- Intellectual Disability.
- Score at or above 5 on the PANSS ( Hostility and Uncooperativeness); score at or above 6 on the PANSS (suspiciousness).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Meta-cognitive Training
The metacognitive training program is comprised of eight modules targeting common cognitive errors in schizophrenia. The modules are : attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8). The treatment group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group. |
|
|
Active Comparator: Psychoeducational group
In the control group the modules worked were: 1. Healthy Habits, 2. Risk Behaviors, 3. Prevention of relapse, 4 and 5.Videoforum, 6. Resources of work and development of curriculum vitae 7. Leisure activities, and 8. Resources of the community.
The psychoeducational group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PANSS. Positive and Negative Syndrome Scale
Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up
|
The Positive and Negative Syndrome Scale (PANSS)(Kay et al., 1987; Peralta and Cuesta, 1994) measures 30 symptoms on a scale of 1-7, with higher scores indicating greater psychopathology.
The PANSS contains three sub-scales: positive, negative and general symptoms.
|
baseline, 2 months (post-treatment) and 6 months of follow-up
|
|
PSYRATS. Psychotic Symptoms Rating Scale
Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up
|
The PSYRATS (Haddock et al, 1999; Gonzalez et al, 2003).
This scale assess delusions in 6 items.
|
baseline, 2 months (post-treatment) and 6 months of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Jumping to conclusions
Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up
|
Three different computer tasks were used in the study.
In Task 1, jars contained balls of two different colors; in one of them the proportion was 85 black versus 15 orange balls and in the other the ratio was reversed.
Task 2 was the same as Task 1 but with a proportion of 60:40 in each jar.
Finally, Task 3 was similar to Task 2 but instead of balls, the jars contained positive or negative comments with a proportion of 60:40.
The patients had to decide which to jar belonged the extracted balls or comments.
At all times the participants had information about the balls previously extracted, in order to control the effect of memory.
The subjects could remove as many balls as needed to make their final decision (Garety et al., 2005).
JTC was considered as taking a decision after extracting 1 or 2 balls.
|
baseline, 2 months (post-treatment) and 6 months of follow-up
|
|
BCIS. Beck Cognitive and Insight Scale
Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up. Moreover in the intervention group this scale was assessed at the end of each session
|
The Beck Cognitive Insight Scale (BCSI; Beck et al., 2004; Gutierrez-Zotes et al., 2012) is a self-registering measure of 15 items which evaluates how the patients assess their own judgement.
It has two dimensions; self-reflection (R) (9 items), and self-certainty (C) (6 items).
A compound index of cognitive insight is obtained as the subtraction of self-certainty from self-reflection (R-C).
|
baseline, 2 months (post-treatment) and 6 months of follow-up. Moreover in the intervention group this scale was assessed at the end of each session
|
|
IPSAQ. Internal, Personal and Situational Attribution Questionnaire.
Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up.
|
The scale assess the attributional style in 32 situations.
|
baseline, 2 months (post-treatment) and 6 months of follow-up.
|
|
Hinking Task
Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up.
|
The Scale assess Theory of Mind.
For the porpouse of the study we selected 3 different situations in each assessment
|
baseline, 2 months (post-treatment) and 6 months of follow-up.
|
|
TCI scale "Test de Creencias Irracionales"
Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up.
|
This scale assess irrational beliefs in ten subscales:Need for acceptance by others, High self-expectations, blame, Intolerance to frustration, Worry and anxiety, Emotional irresponsibility, Avoidance of problems, dependency, helplessness, perfectionism.
|
baseline, 2 months (post-treatment) and 6 months of follow-up.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SFS "Social Functioning Scale"
Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up.
|
This scale assess social functioning in people with psychotic disorders (Birchwood et al, 1990; Torres y Olivares, 2000).
|
baseline, 2 months (post-treatment) and 6 months of follow-up.
|
|
Neuropsychological battery
Time Frame: baseline and 6 months of follow-up.
|
A neuropsychological battery was included.
The test included were WCST(Wisconsin Card Sorting Test, Bergs et al, 1948)measure of executive function; Test Stroop (Stroop, 1935) flexibility and inhibition of automatic responses; TMTA-B (Trail Making Test, Reitan, 1993) visual attention and task switching; CPT (Continous Performance Test, Conners 2000) this scale asses inattentiveness and impulsivity; TAVEC (Test Aprendizaje Verbal España Complutense, Benedet and Aleixandre 1998) this scale asses memory; WAIS (Weschler Adults Intelligence Scale, Wechsler 1955)subscales of digits and vocabulary.
|
baseline and 6 months of follow-up.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Susana Ochoa, PhD, Parc Sanitari Sant Joan de Deu
- Study Chair: Marisa Barrigón, PhD, Servicio Andaluz de Salud. Granada
- Study Chair: Fermín González, Servicio Andaluz de Salud. Jaen
- Study Chair: Isabel Ruiz, Servicio Andaluz de Salud. Málaga
- Study Chair: Eva Grasa, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Study Chair: Esther Pousa, PhD, Corporación Parc Taulí
- Study Chair: Esther Lorente, PhD, Hospital Clinic de Valencia
- Study Chair: Ana Barajas, Centre d'Higiene Mental de les Corts
- Study Chair: Jordi Cid, Institut d'Assistència Sanitària de Girona
- Study Chair: Raquel López, MS, Parc Sanitari Sant Joan de Deu
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI11/01347
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychosis
-
Columbia UniversityNational Institute of Mental Health (NIMH); University of California, Davis; University... and other collaboratorsRecruitingClinical High Risk | First Episode Psychosis | Early PsychosisUnited States
-
University of OxfordWellcome Trust; Jazz PharmaceuticalsNot yet recruitingClinical High Risk for Psychosis | Clinical High Risk for Psychosis (CHR) | Clinical High Risk for Developing PsychosisUnited Kingdom, Italy, Greece, Finland, Germany, Netherlands, Austria, Canada, Spain, Switzerland
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)Enrolling by invitationFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
University of New MexicoNational Institute of Mental Health (NIMH)CompletedPsychosis | Clinical High Risk for Psychosis | First Episode PsychosisUnited States
-
Elazığ Mental Health and Diseases HospitalRecruitingMethamphetamine Induced PsychosisTurkey (Türkiye)
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingClinical High Risk | First Episode Psychosis | Early PsychosisUnited States
-
Shanghai Jiao Tong University School of MedicineGuangzhou Psychiatric Hospital; Suzhou Psychiatric Hospital; Tianjin Anding Hospital and other collaboratorsRecruitingSchizophrenia; Psychosis | Clinical High Risk | First Episode PsychosisChina
-
University of OxfordHospital General Universitario Gregorio Marañon; Charite University, Berlin... and other collaboratorsNot yet recruitingPsychosis | Treatment Resistant PsychosisSpain, United Kingdom, Germany, Israel, Greece, Italy, Netherlands, Switzerland
-
Chulalongkorn UniversityNational Research Council of Thailand; Thanyarak InstituteCompletedMethamphetamine-induced PsychosisThailand
-
Université de SherbrookeBaszucki Brain Research FundNot yet recruitingMetabolic Disease | Psychosis; Episode | First Episose PsychosisCanada
Clinical Trials on Psychoeducational group
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Hospital Universitari Vall d'Hebron Research Institute; Centre d'Higiene Mental...UnknownDepressive DisordersSpain
-
Rambam Health Care CampusUnknownPatients Diagnosed With Severe Mental IllnessIsrael
-
University of SalamancaCompleted
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedMental Health DisordersNorway
-
University Hospital, MontpellierCHU Marius Lacroix, Lille, FRANCE; CHU Gabriel Montpied, Clermont Ferrand,... and other collaboratorsRecruiting
-
Bambino Gesù Hospital and Research InstituteEuropean UnionCompleted
-
Region StockholmKarolinska InstitutetNot yet recruiting
-
University of British ColumbiaCompleted
-
Clinica Universidad de Navarra, Universidad de...Completed
-
Instituto de Investigación Hospital Universitario...Carlos III Health Institute; European Regional Development FundCompletedSchizophrenia and Disorders With Psychotic Features | Psychotic EpisodeSpain